VR Logo

Vaccinex Inc. (VCNX) download report


Healthcare | Biotechnology & Pharma Research

Vaccinex Inc. (VCNX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs.

IPO Date: 09-Aug-2018

Co-Founder, CEO, Pres & Director: Dr. Maurice Zauderer Ph.D.

Chief Financial Officer: Mr. Scott E. Royer C.F.A., M.B.A.

Listing: NASDAQ: VCNX

Country: United States

Headquarters: Rochester, NY

Website: https://www.vaccinex.com

Key Facts

Market cap: $46.50 Mln

Revenue (TTM): $0.90 Mln

Earnings (TTM): $-20.40 Mln

Cash: $16.80 Mln

Total Debt: $0.33 Mln

Insider's Holding: 12.06%

Liquidity: Low

52 Week range: $0.90 - 2.91

Shares outstanding: 42,664,100

6 Years Aggregate:

  • CFO: $-151.04 Mln
  • EBITDA: $-147.21 Mln
  • Net Profit: $-145.28 Mln

Stock Performance

Time Period Vaccinex (VCNX) S&P BSE Sensex* S&P Small-Cap 600*
YTD3.85-8.97-18.40
1 month-14.96-3.38-8.42
3 months-22.30-7.93-14.06
1 Year-63.010.55-17.64
3 Years-40.2010.416.75
5 Years--11.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
Year Vaccinex (VCNX) S&P Small-Cap 600 S&P BSE Sensex
2021-49.7625.2721.99
2020-57.329.5715.75
201933.0720.8614.38